Age
Item
18 years of age or order
boolean
C0001779 (UMLS CUI [1])
Idiopathic pulmonary hypertension Secondary to Scleroderma | Pulmonary arterial hypertension Secondary to Scleroderma | Lupus Erythematosus, Systemic | Appetite Depressants | HIV Infections
Item
current diagnosis of either pph orpah secondary to the scleroderma spectrum of disease, systemic lupus erythematosus, anorexigen use, or hiv infection at the screening visit
boolean
C0152171 (UMLS CUI [1,1])
C0175668 (UMLS CUI [1,2])
C0011644 (UMLS CUI [1,3])
C2973725 (UMLS CUI [2,1])
C0175668 (UMLS CUI [2,2])
C0011644 (UMLS CUI [2,3])
C0024141 (UMLS CUI [3])
C0003620 (UMLS CUI [4])
C0019693 (UMLS CUI [5])
Catheterization of right heart Complete | Criteria hemodynamic Pre-specified Fulfill
Item
right heart catheterization, completed prior to screening visit must meet pre-specified hemodynamic criteria
boolean
C0189896 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
C0243161 (UMLS CUI [2,1])
C0019010 (UMLS CUI [2,2])
C2826245 (UMLS CUI [2,3])
C1550543 (UMLS CUI [2,4])
Childbearing Potential Serum pregnancy test negative | Childbearing Potential Barrier Contraception double
Item
female subjects of childbearing potential must have a negative serum pregnancy test and must agree to use a reliable double barrier method of contraception until study completion and for at least four weeks following their final study visit
boolean
C3831118 (UMLS CUI [1,1])
C0430061 (UMLS CUI [1,2])
C3831118 (UMLS CUI [2,1])
C0004764 (UMLS CUI [2,2])
C0205173 (UMLS CUI [2,3])
Gender | Informed Consent | Atrophic seminiferous tubules Risk Associated with Investigational New Drug | Male infertility Risk Associated with Investigational New Drug
Item
male subjects must be informed of the potential risks of testicular tubular atrophy and infertility associated with taking this study drug and queried regarding his understanding of the potential risks as described in the informed consent form
boolean
C0079399 (UMLS CUI [1])
C0021430 (UMLS CUI [2])
C1968705 (UMLS CUI [3,1])
C0035647 (UMLS CUI [3,2])
C0332281 (UMLS CUI [3,3])
C0013230 (UMLS CUI [3,4])
C0021364 (UMLS CUI [4,1])
C0035647 (UMLS CUI [4,2])
C0332281 (UMLS CUI [4,3])
C0013230 (UMLS CUI [4,4])
Pulmonary arterial hypertension Associated with Congenital heart disease | Pulmonary arterial hypertension Associated with Coronary Artery Disease | Pulmonary arterial hypertension Associated with Heart Disease Left sided | Pulmonary arterial hypertension Associated with Lung Diseases, Interstitial | Pulmonary arterial hypertension Associated with Chronic Obstructive Airway Disease | Pulmonary arterial hypertension Associated with Venoocclusive disease | Pulmonary arterial hypertension Associated with Thrombosis chronic | Pulmonary arterial hypertension Associated with Embolism chronic | Pulmonary arterial hypertension Associated with Sleep Apnea
Item
pah due to or associated with congenital heart disease, coronary artery disease, left heart disease, interstitial lung disease, chronic obstructive pulmonary disease, veno-occlusive disease, chronic thrombotic and/or embolic disease, or sleep apnea
boolean
C2973725 (UMLS CUI [1,1])
C0332281 (UMLS CUI [1,2])
C0152021 (UMLS CUI [1,3])
C2973725 (UMLS CUI [2,1])
C0332281 (UMLS CUI [2,2])
C1956346 (UMLS CUI [2,3])
C2973725 (UMLS CUI [3,1])
C0332281 (UMLS CUI [3,2])
C0018799 (UMLS CUI [3,3])
C0443246 (UMLS CUI [3,4])
C2973725 (UMLS CUI [4,1])
C0332281 (UMLS CUI [4,2])
C0206062 (UMLS CUI [4,3])
C2973725 (UMLS CUI [5,1])
C0332281 (UMLS CUI [5,2])
C0024117 (UMLS CUI [5,3])
C2973725 (UMLS CUI [6,1])
C0332281 (UMLS CUI [6,2])
C0948441 (UMLS CUI [6,3])
C2973725 (UMLS CUI [7,1])
C0332281 (UMLS CUI [7,2])
C0040053 (UMLS CUI [7,3])
C0205191 (UMLS CUI [7,4])
C2973725 (UMLS CUI [8,1])
C0332281 (UMLS CUI [8,2])
C0013922 (UMLS CUI [8,3])
C0205191 (UMLS CUI [8,4])
C2973725 (UMLS CUI [9,1])
C0332281 (UMLS CUI [9,2])
C0037315 (UMLS CUI [9,3])
Portopulmonary hypertension
Item
portopulmonary hypertension
boolean
C1868851 (UMLS CUI [1])
bosentan
Item
bosentan within four weeks prior to screening
boolean
C0252643 (UMLS CUI [1])
Phosphodiesterase 5 inhibitor | Prostaglandins chronic
Item
phosphodiesterase type v inhibitor or chronic prostanoid therapy within four weeks prior to screening
boolean
C1318700 (UMLS CUI [1])
C0033554 (UMLS CUI [2,1])
C0205191 (UMLS CUI [2,2])
Cardiotonic Agents Intravenous
Item
iv inotrope use within two weeks prior to screening
boolean
C0007209 (UMLS CUI [1,1])
C1522726 (UMLS CUI [1,2])
Alanine aminotransferase increased | Aspartate aminotransferase increased
Item
alt or ast lab value that is greater than 1.5 times the upper limit of normal
boolean
C0151905 (UMLS CUI [1])
C0151904 (UMLS CUI [2])
Pulmonary function tests | Criteria Pre-specified Fulfill
Item
pulmonary function tests not meeting pre-specified criteria
boolean
C0024119 (UMLS CUI [1])
C0243161 (UMLS CUI [2,1])
C2826245 (UMLS CUI [2,2])
C1550543 (UMLS CUI [2,3])
Medical contraindication Endothelin receptor antagonist
Item
contraindication to treatment with an era
boolean
C1301624 (UMLS CUI [1,1])
C1134681 (UMLS CUI [1,2])
Malignant Neoplasms | Basal cell carcinoma | Carcinoma in situ of uterine cervix
Item
history of malignancies other than basal cell carcinoma of the skin or in situ carcinoma of the cervix within the past five years
boolean
C0006826 (UMLS CUI [1])
C0007117 (UMLS CUI [2])
C0851140 (UMLS CUI [3])
Pregnancy | Breast Feeding
Item
females who are pregnant or breastfeeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])